The HCPLive Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.
May 6th 2024
Data from the ORCA-V trial suggests cytisinicline, a plant-based medication, aids adults in quitting e-cigarettes.
Boehringer Ingelheim Announces $35 Monthly Price Cap on Inhalers for Asthma, COPD Patients
March 7th 2024On March 07, 2024, Boehringer Ingelheim announced it would be instituting a $35 per month out-of-pocket cost cap for its portfolio of inhaler products, with this cap going into effect on June 01, 2024.
Few Benefits Observed with Rapid Respiratory Virus Testing in Emergency Departments
This analysis looked into whether rapid respiratory virus testing in patients with suspected acute respiratory infection was linked to such outcomes as antibiotic use decrease and hospitalization.
Experts' Perspectives: How Lacking Clinical Trial Diversity Impacts Public Health
March 1st 2024This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.
Optimal Treatment Sequence Identified for Out-of-Hospital Cardiac Arrest
Additional research may be necessary to look at the sequence of epinephrine administration and advanced airway management in settings in which alternative epinephrine administration strategies are utilized.
60 Years of Progress: How the 1964 Surgeon General Report has Shaped Modern Healthcare
January 31st 2024In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.